Fluphenazine
Test Mnemonic
FLUPH
CPT Codes
- 80342 - QTY (1)
LOINC ®
3650-9
Aliases
- Dapotum
- Lyogen
- Moditen
- Omca
- Permitil
- Prolixin
- Sediten
Includes
- Fluphenazine
Performing Laboratory
ARUP
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 1 mL | Serum | No additive (Red) | Refrigerated | Pre-dose (trough) draw - At steady state concentration. Do not use serum separator tubes. Separate serum from cells within 2 hours of collection and transfer to standard aliquot tube. |
Alternate Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 1 mL | Plasma | EDTA (Lavender) | Refrigerated | Pre-dose (trough) draw - At steady state concentration. Do not use plasma separator tubes. Separate plasma from cells within 2 hours of collection and transfer to standard aliquot tube. |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 0.5 mL |
Stability
| Environmental Condition | Description |
|---|---|
| Ambient | After separation from cells: 48 hours |
| Frozen | After separation from cells: 1 month (Avoid repeated freeze/thaw cycles) |
| Refrigerated | After separation from cells: 1 week |
Days Performed
Mon, Wed, Fri
Turnaround Time
2 - 9 days
Methodology
| Name | Description |
|---|---|
| Quantitative Liquid Chromatography - Tandem Mass Spectrometry |
Reference Range
| Fluphenazine | |||||
|---|---|---|---|---|---|
| Sex | Age From | Age To | Type | Range | Range Unit |
| Therapeutic Range pre-dose (trough) draw at steady-state concentration: 1.0-10.0 ng/mL | Toxic: Greater than 15 ng/mL |
Special Info
Measure at least 2 weeks after initiating treatment. Specimen should be collected prior to next dose - at steady state concentration. Specimens that are unspun, hemolyzed, or collected in gel separator tubes will be rejected. This test is New York state approved.
Clinical Info
This test is useful to optimize drug therapy and monitor patient adherence. The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Adverse effects may include extrapyramidal symptoms, seizures and neuroleptic malignant syndrome.